Breaking Biotech (@BreakingBioMatt) header
Breaking Biotech (@BreakingBioMatt) profile picture

Biotech investor/trader - Host of Breaking Biotech https://xitter.cf/t.co/P6wtEkED8z breakingbiomatt@gmail.com

San Diego, CA
Joined September 2017
Replying to @HakenWim
Thanks Wim! On point 1), I can see it in both directions. If fibrosis is worse in F3 patients then there's more of an opportunity for Lanfibranor to have an effect. BUT, if the bridged fibrosis is more difficult to resolve at that level, Lanifibranor needs to have a strong anti-fibrotic effect. Based on the P2 data for >1 stage improvement in fibrosis, it seems like it's the harder of the 3 endpoints to hit. On 3), I actually agree about my target being conservative on the upside, but I can't help but think about how hard it will be to launch a MASH drug with Rezdiffra and GLP-1s out there. I guess that's a concern for 2028
3
80
San Diego biotech Iambic $IAM going public today. Several partnerships with big players. Touting its AI model as their secret to doing better drug development. Still early stage, but lead program IAM1363 should be interesting readout - testing basket of HER2-altered cancers. Expecting to start registrational trial in 2027...so data within the next year or so?
3
1
1
9
3,131
Wow, painful seeing this for the shorts $MRNA
2
451
$ANNX The Q4 readout is a bit convoluted. The entire 659 patient trial is split into 2 (prespecified) independent statistical sub-studies. If Vonaprument hits the primary endpoint on all 3 studies for 15 mo, they will unmask, present the data and prepare for filing...I guess in Q4? Any communication about continuing to 24 mo alone means negative for 15 mo
1
1
4
1,216
Replying to @plainyogurt21
Aren't the discontinuations pretty balanced?
1
272
Well, congrats to the longs $KOD. This graph says it all though imo. Avg durability of q18w is fine, but is it really an Eylea killer? Don't forget this is after 4 loading doses.
4
19
7,084
113 - Vaxxinity Takes on Neurodegenerative Diseases with Vaccines - Potential Short Opportunity? $VAXX $BIIB $ACHV youtu.be/VlF6HvZjsV4
1
5
111 - Achieve Life Sciences Phase 3 Readout Imminent! Interview with CEO John Bencich $ACHV youtu.be/NEAzxbP-eEY
2
8